Neuraxis Inc. experienced a significant price increase of 18.06%, reaching a 20-day high amid positive market conditions, with the Nasdaq-100 up 0.41% and the S&P 500 up 0.23%.
This surge is attributed to Neuraxis announcing that its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, has received medical policy coverage from a major national health insurer, impacting approximately 45 million health plan members. This coverage is expected to enhance the therapy's market recognition and drive substantial revenue growth, especially with the implementation of a Category I CPT code effective January 1, 2026.
The implications of this development are significant, as it positions Neuraxis for increased clinical recognition and revenue potential in the medical technology sector, addressing a critical unmet need in pediatric functional dyspepsia treatment.
Wall Street analysts forecast NRXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRXS is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast NRXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRXS is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.660
Low
8.00
Averages
8.00
High
8.00
Current: 4.660
Low
8.00
Averages
8.00
High
8.00
Craig-Hallum
Buy
maintain
$7 -> $8
2025-12-22
Reason
Craig-Hallum
Price Target
$7 -> $8
AI Analysis
2025-12-22
maintain
Buy
Reason
Craig-Hallum raised the firm's price target on Neuraxis to $8 from $7 and keeps a Buy rating on the shares after the company announced that they have been included in coverage from a large, national payer. This coverage expansion adds approximately 45M lives, bringing total national coverage for IBStim to nearly 100M. The Anthem win adds coverage for as much as 20% of NeurAxis's pediatric opportunity, and the firm believes it really unlocks the opportunity itself.
Craig-Hallum
Chase Knickerbocker
Buy
initiated
$7
2025-06-17
Reason
Craig-Hallum
Chase Knickerbocker
Price Target
$7
2025-06-17
initiated
Buy
Reason
Craig-Hallum analyst Chase Knickerbocker initiated coverage of Neuraxis with a Buy rating and $7 price target.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NRXS
Unlock Now
Craig-Hallum
Chase Knickerbocker
Buy
initiated
$7
2025-06-17
Reason
Craig-Hallum
Chase Knickerbocker
Price Target
$7
2025-06-17
initiated
Buy
Reason
As previously reported, Craig-Hallum analyst Chase Knickerbocker initiated coverage of Neuraxis with a Buy rating and $7 price target. The firm says this is a classic overlooked micro-cap medtech story that it believes will appear to be an overnight success story, though it was many years in the making. Neuraxis is introducing innovation into a space that does not get a lot of attention, namely pediatric functional abdominal pain. Craig-Hallum is highlighting the company's product IB-Stim as a potentially transformative therapy for pediatric functional abdominal pain disorders. The company targets a $3.7B market in severely debilitated patients, and the firm believes Neuraxis could very realistically reach $130M in revenue at just 4% penetration.
About NRXS
Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company’s second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
